menu search

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 10:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 10:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Molecular templates, inc. to present interim results on mt-5111 at the 45th annual san antonio breast cancer symposium (sabcs) and participate at the 64th american society of hematology (ash) annual m

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

December 2, 2022, 5:02 pm

Merck (mrk) keytruda advanced gastric cancer study meets goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced...

November 23, 2022, 1:33 pm

Volitionrx ends q3 with $16.4 million cash, moves from r&d to commercial cancer screening company

VolitionRx (NYSE-A:VNRX) said it ended third-quarter 2022 with US$16.4 million in cash and cash equivalents, thanks to careful management of expenditu...

November 15, 2022, 9:14 am

Why macrogenics stock crushed the market on monday

Positive momentum continues for the cancer specialist in the wake of its latest earnings report....

November 14, 2022, 6:31 pm

Volitionrx teams up with leading french veterinary group to assess potential of cancer screening technology

VolitionRx (NYSE-A:VNRX) Limited said it will work with a renowned French veterinary referral clinic to further assess the potential of its ...

November 14, 2022, 9:18 am

Why shares of neogenomics jumped 53.9% this week

The cancer screening company showed its turnaround may be working....

November 11, 2022, 5:36 pm

Glycomimetics could surge if q1 data readout is positive

GlycoMimetics stock price jumped on November 9. Good cancer survival results may have lengthened the ti...

November 11, 2022, 11:22 am

Why amgen's cancer drug results gave this small cap a big boost

Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival ...

August 31, 2022, 12:04 pm

Soligenix shares gain on hybrytes data from blood cancer study

Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphom...

July 20, 2022, 3:19 pm


Search within

Pages Search Results: